- Home
- NAKA vs SGMT Comparison
NAKA vs SGMT Comparison
Compare NAKA & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NAKA | SGMT |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.8M | 169.4M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NAKA | SGMT |
|---|---|---|
| Price | $5.08 | $9.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $0.75 | ★ $26.13 |
| AVG Volume (30 Days) | 184.2K | ★ 1.1M |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.19 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | $1,514.38 | N/A |
| Revenue Next Year | $48.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $4.50 |
| 52 Week High | $15.60 | $10.06 |
Technical Indicators
Market Signals| Indicator | NAKA | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 74.32 |
| Support Level | $4.12 | $6.62 |
| Resistance Level | $5.11 | N/A |
| Average True Range (ATR) | 0.38 | 0.56 |
| MACD | 0.01 | 0.25 |
| Stochastic Oscillator | 78.87 | 86.61 |
Price Performance
Historical ComparisonAbout NAKA Kindly MD Inc.
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.